What TRIUMPH-1 Means for Canadians: Access, Approval, and Next Steps
The landmark TRIUMPH-1 results bring retatrutide closer to Health Canada approval. Here's what the data means for Canadian access timelines and what to watch next.
TRIUMPH-1 Phase 3 Results: Retatrutide Achieves Up to 30.3% Mean Weight Loss
Eli Lilly's triple-agonist retatrutide delivered bariatric-surgery-level weight loss in the pivotal TRIUMPH-1 Phase 3 obesity trial, with participants losing up to 30.3% of body weight.
Retatrutide, Gym Culture, and the 'Leanmaxxing' Trend: What You Need to Know
As retatrutide circulates through illicit online markets, gym-goers are using the experimental drug to get 'shredded' — but experts warn of muscle loss, unregulated supply, and serious health risks.
TRIUMPH-4 Completes: Retatrutide Studied in Obesity-Related Knee Osteoarthritis
The Phase 3 trial testing retatrutide in patients with obesity and knee osteoarthritis has completed, with 10 Canadian sites participating. Results could expand the drug's potential indications beyond weight loss alone.
Phase 2 Results Published in NEJM: Retatrutide Achieves 24% Weight Loss at 48 Weeks
The landmark Phase 2 trial of retatrutide published in the New England Journal of Medicine showed dose-dependent weight loss up to ~24% — results that set the stage for the Phase 3 TRIUMPH program.